الخبر ترى زين والشركة يمكن تنزل الى 2.75 وتصير صيدة
Spectrum Pharmaceuticals Licenses RenaZorb(TM) From Altair Nanotechnologies
Monday January 31, 8:50 am ET
* RenaZorb(TM) second-generation lanthanum-based phosphate binders which utilize Altair's proprietary lanthanum nanomaterial technology have the potential to address a multi-billion dollar market opportunity for the treatment of hyperphosphatemia in patients with chronic kidney disease and end-stage renal disease
الشركة له مجالات عدة